Video Library & Webinars | Oncotype DX Test

Evolution of Genomic Assays for Early Breast Cancer: What You Need to Know in 2025

Loading component...

Agenda:

Introduction – Dr. Chia

Case 1: Considerations for Anthracycline Use in HR+/HER2- Early Breast Cancer – Dr. Sehdev

Case 2: Hormone Levels in Premenopausal Patients and Chemotherapy Response – Dr. Boileau

Case 3: Using Core Biopsies for Genomic Risk Profiling and Neoadjuvant Treatment Decisions – Dr. Brezden-Masley

Case 4: Decision-Making in Borderline Genomic Risk Scores – Dr. Chia

Q&A – All

October 7, 2025.

Loading component...

Evolution of Genomic Assays for Early Breast Cancer: What You Need to Know in 2025

Dr. Stephen Chia: Welcome and Introduction to the EDGE Program

Dr. Sandeep Sehdev: Considerations for Anthracycline Use in HR+/HER2- Early Breast Cancer

Dr. Jean-François Boileau: Hormone Levels in Premenopausal Patients and Chemotherapy Response

Dr. Christine Brezden-Masley: Using Core Biopsies for Genomic Risk Profiling and Neoadjuvant Treatment Decisions

Dr Stephen Chia: Decision-Making in Borderline Genomic Risk Scores

Q&A session with breast cancer expert panelists

Loading component...

ESMO Breast Cancer 2025

Key Messages from the Exact Sciences Symposium

Professor Marc A. Thill: Welcome and Introduction

Professor Frédérique Penault-Llorca: Unlocking the Oncotype DX Breast Recurrence Score^® Test: Unique design and development to bring clarity to treatment decisions

Professor Christos Sotiriou: Emerging Trends on Treatment Guidance in Early Breast Cancer: Unveiling clinical implications from latest updates from TAILORx and RxPONDER

Professor Marc A. Thill: Advancing Treatment Approaches and Neoadjuvant Therapy in Early Breast Cancer: Evidence-based strategies

Loading component...

19th St. Gallen International Breast Cancer Conference

Key Messages from the Exact Sciences Symposium

Professor Shani Paluch-Shimon: Optimizing systemic treatment choices using the Oncotype DX BreastRecurrence Score Result pre-operatively

Professor, Stephen Chia MD, FRCP(C): Directing Neoadjuvant Chemotherapy (NAC) using the Oncotype DXBreast Recurrence Score Result

Mr Henry Cain: Genomic testing on excision sample vs core biopsy: What we can learn from PreDX?

Patient perspectives: A round table discussion with Prof. Stephen Chia, Prof. Shani Paluch Shimon, and Mr Henry Cain

Loading component...

Events based video library

ESMO 2024 Satellite symposium recording

[ESMO24] Evolving role of genomic assays in early breast cancer

Prof. Miguel Martin discusses the application of genomic assays in the neoadjuvant setting

[ESMO24] Tissue-based genomics to guide adjuvant therapy decisions

Prof. Janice Walshe discusses the impact of the introduction of genomic assays on clinical practice for both clinicians and patients.

[ESMO24] Introduction to MRD in breast cancer

Prof. Nicholas Turner provides a brief overview of the concept and terms related to molecular residual disease.

[ESMO24] Evolving role of MRD guided decision making in early breast cancer

Prof. Sherene Loi presented at ESMO 2024 an update on the current data and ongoing studies on molecular residual disease in early breast cancer.

[ESMO24] Optimizing the approach to MRD assay development

Rick Baehner provides a topline overview of ongoing research into the development of MRD assays.

EBCC 2024 Satellite symposium recording

[EBCC24] Evolving clinical practice for multi-gene assays: what’s new!

Evolving clinical practice for multi-gene assays: what’s new!

[EBCC24] Implications of updated guidelines for MGAs: Introduction

Implications of updated guidelines for MGAs: Introduction

[EBCC24] Implementation of guidelines into clinical practice: expert discussion on challenging cases - Large tumour

Implementation of guidelines into clinical practice: expert discussion on challenging cases - Large tumour

[EBCC24] Implementation of guidelines into clinical practice: expert discussion on challenging cases - Elderly patient

Professor Laura Biganzoli presented a challenging case study of an elderly patient with early breast cancer, focusing on the important interplay between genomic tools and patients’ characteristics.

[EBCC24] Challenging cases: N1 – premenopausal

Professor Christian Kurzeder presented a challenging case study of a N1 premenopausal patient, focusing on how ODX and clinical evidence may help...

Loading component...

Listen Rick Baehner, MD and Helen Bailey, MD share insights of a centralized laboratory & give perspectives how expertise in genomic testing will...

Loading component...

Hear Prof. Giancarlo Pruneri of the University of Milan providing his insights on the importance of analytical work and the critical need to...

Loading component...

Rick Baehner, MD - Exact Science’s Chief Medical Officer, presents on the analytical validation and the key clinical attributes of the the Oncotype...

Loading component...

Rick Baehner, MD - Exact Science’s Chief Medical Officer, presents on the clinical validation of the Oncotype DX^® test in TAILORx (N0 population)...

Loading component...

Rick Baehner, MD - Exact Science’s Chief Medical Officer, presents on the Oncotype DX^® test in ongoing trials.

Loading component...

Hear Drs. Jeremy Force and Christy Russell discuss how physicians can use the Breast Recurrence Score test and the recently presented data from the RxPONDER trial to inform chemotherapy decisions for HR-positive, HER2-negative breast cancer patients.

Loading component...

At the 2021 Miami Breast Cancer Conference, Drs. Tari King and Kathy Miller discuss lymph node-positive breast cancer cases with Dr. Christy Russell.

Loading component...

Have questions about Oncotype DX^®?

Doctor sitting with patient having a discussion.

Video Library

Loading component...

Agenda:

Loading component...

Evolution of Genomic Assays for Early Breast Cancer: What You Need to Know in 2025

Loading component...

Loading component...

19th St. Gallen International Breast Cancer Conference

Loading component...

[ESMO24] Evolving role of genomic assays in early breast cancer

[ESMO24] Tissue-based genomics to guide adjuvant therapy decisions

[ESMO24] Introduction to MRD in breast cancer

[ESMO24] Evolving role of MRD guided decision making in early breast cancer

[ESMO24] Optimizing the approach to MRD assay development

[EBCC24] Evolving clinical practice for multi-gene assays: what’s new!

[EBCC24] Implications of updated guidelines for MGAs: Introduction

[EBCC24] Implementation of guidelines into clinical practice: expert discussion on challenging cases - Large tumour

[EBCC24] Implementation of guidelines into clinical practice: expert discussion on challenging cases - Elderly patient

[EBCC24] Challenging cases: N1 – premenopausal

Loading component...

Loading component...

Loading component...

Loading component...

Loading component...

Loading component...

Loading component...

Loading component...

Loading component...

Get in touch

Loading component...

Loading component...

Loading component...

Loading component...

Agenda:

Evolution of Genomic Assays for Early Breast Cancer: What You Need to Know in 2025

[ESMO24] Evolving role of genomic assays in early breast cancer

[ESMO24] Tissue-based genomics to guide adjuvant therapy decisions

[ESMO24] Introduction to MRD in breast cancer

[ESMO24] Evolving role of MRD guided decision making in early breast cancer

[ESMO24] Optimizing the approach to MRD assay development

[EBCC24] Evolving clinical practice for multi-gene assays: what’s new!

[EBCC24] Implications of updated guidelines for MGAs: Introduction

[EBCC24] Implementation of guidelines into clinical practice: expert discussion on challenging cases - Large tumour

[EBCC24] Implementation of guidelines into clinical practice: expert discussion on challenging cases - Elderly patient

[EBCC24] Challenging cases: N1 – premenopausal

Get in touch